Skip to main content
. 2014 Sep 30;37(10):597–604. doi: 10.1002/clc.22327

Figure 1.

CLC-22327-FIG-0001-b

(A) Study design for OPTIONS I. (B) Study design for OPTIONS II. *75 mg SC Q2W with titration (as necessary) to 150 mg SC Q2W. Abbreviations: NCEP ATP III TLC, National Cholesterol Education Program–Adult Treatment Panel III Therapeutic Lifestyle Changes; Q2W, every 2 weeks; R, randomization; SC, subcutaneous.